Results 21 to 30 of about 45,662 (251)

Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2022
ObjectiveHeart failure (HF) and atrial fibrillation (AF) are often coexisting. They have common risk factors and pathophysiologic mechanisms. Sacubitril/valsartan has shown efficacy and tolerability in patients with HF.
Xuehui Liu, Hongjun Liu, Lijun Wang, Lei Zhang, Qiang Xu   +4 more
doaj   +2 more sources

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine, 2022
BackgroundSacubitril/valsartan therapy reduced the risks of death and of hospitalization for heart failure (HF). HF and cardiac arrhythmias have shared physiological mechanisems.
Xue-Hui Liu, Xue-Hui Liu, Guan-Ling Wang, Qiang Xu, Qiang Xu, Lei Zhang, Lei Zhang, Hong-Jun Liu, Hong-Jun Liu   +8 more
doaj   +1 more source

Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]

, 2017
The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella, Triposkiadis, Filippos   +1 more
core   +2 more sources

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats

Pharmaceutics, 2020
Background: Portal hypertension is characterized by exaggerated activation of the renin-angiotensin-aldosterone axis. Natriuretic peptide system plays a counter-regulatory role, which is modulated by neprilysin.
Shao-Jung Hsu, Hui-Chun Huang, Chiao-Lin Chuang, Ching-Chih Chang, Ming-Chih Hou, Fa-Yauh Lee, Shou-Dong Lee   +6 more
doaj   +1 more source

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies

Journal of Cardiovascular Development and Disease, 2022
Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the ...
Hisham A. Badreldin, Nasser Aldosari, Lama Alnashwan, Taif Almutairi, Nada Yousif, Khalid Alsulaiman, Ohoud Aljuhani, Awatif Hafiz, Omar Alshaya   +8 more
doaj   +1 more source

Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure [PDF]

, 2018
Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Claggett, Brian, Damman, Kevin, Desai, Akshay S., Gori, Mauro, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Prescott, Margaret F., Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +14 more
core   +4 more sources

Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway

Analytical Cellular Pathology, 2022
Objective. Valsartan has been studied to exert effects on kidney disease. However, the concrete function of valsartan in combination with tripterygium glycosides in chronic nephritis remained largely unknown. The study was designed to unravel the impacts
Jiabao Dong, Duo Huang, Ling Jing, Mengmeng Wu   +3 more
doaj   +1 more source

Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2018
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs.
Abraham, Andersen, Anker, Anker, Borer, Ghosh, Greenberg, Lin, McMurray, McMurray, Metcalfe, Neaton, Packer, Rogers, Rogers, Rogers, Rogers, Solomon, Wei   +18 more
core   +3 more sources

Depression associated with valsartan, angiotensin II receptor antagonist; case report and review of the literature

Psychiatry and Clinical Psychopharmacology, 2021
Severe depression with suicidal ideation associated with the use of the valsartan , an angiotensin receptor antagonist, is reported. The patient, who was unresponsive to antidepressant medication with two different groups, dramatically recovered ...
Numan Konuk, Mustafa Aydın, Ömer Akay
doaj  

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundThere is a paucity of data about the mechanisms by which sacubitril/valsartan (also known as LCZ696) improves outcomes in patients with heart failure. Specifically, the effects of sacubitril/valsartan on vascular function and NO bioavailability
Rishi K. Trivedi, David J. Polhemus, Zhen Li, Daniel Yoo, Hiroshi Koiwaya, Amy Scarborough, Traci T. Goodchild, David J. Lefer   +7 more
doaj   +1 more source